Growth Hormone Secretagogues Alter Brain Gene Expression in Rats
Background
Growth hormone secretagogues (GHS) are synthetic compounds that stimulate the release of growth hormone (GH). They exert their effects by binding to the GH secretagogue receptor 1a (GHSR-1a), which is highly expressed in the hypothalamus, a brain region critical for appetite and metabolism. While acute GHS effects are well-studied, the long-term impact of central GHS administration on specific neuropeptide gene expression within the arcuate nucleus, a key hypothalamic area, remains unclear.
Results
Chronic central infusion of GHRP-6 significantly altered neuronal activity and neuropeptide gene expression in the arcuate nucleus. > Fos expression, indicating increased neuronal activity, was significantly elevated by 2.8-fold (p<0.01) in the arcuate nucleus of GHRP-6-treated rats compared to controls. Specifically, NPY gene expression showed a 45% increase (p<0.05) and AgRP gene expression was upregulated by 2.1-fold (p<0.01) in the GHRP-6 group. Conversely, POMC gene expression, which typically promotes satiety, exhibited a 30% reduction (p<0.05) compared to vehicle-treated animals. These changes suggest a shift towards an orexigenic (appetite-stimulating) neural state.
Why It Matters
This study provides crucial insights into the neurobiological mechanisms underlying chronic GHS action, particularly their influence on hypothalamic circuits regulating energy balance. The observed upregulation of orexigenic peptides (NPY, AgRP) and downregulation of an anorexigenic peptide (POMC) suggests that chronic GHS use could potentially impact appetite and metabolism beyond just GH release. These findings could inform the development of novel therapeutic strategies for conditions like cachexia (muscle wasting) or growth disorders, while also highlighting potential metabolic side effects that warrant further investigation in human trials. Future research should focus on dose-response relationships and long-term metabolic outcomes.